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Abstract: Introduction: Inflammation contributes to the initiation and progression of atherosclerosis, although the 
underlying inflammatory pathways are not entirely known. Specifically, the role of the proinflammatory soluble CD40 
ligand (sCD40L) on the expression of chronic coronary syndrome (CCS) is not completely understood. We evaluated 
whether sCD40L expression is associated with the presence of CCS and with the clinical and anatomical severity of 
CCS. Methods: We prospectively recruited 94 participants, assigned to two groups matched by age and sex, without 
coronary artery disease (n=26) and with CCS (n=68). Clinical, laboratory and anatomical data were prospectively 
collected, and serum levels of sCD40L were measured. Results: In patients with CCS, classic cardiovascular risk fac-
tors were more prevalent, and the sCD40L levels, leukocyte and neutrophil counts, and neutrophil/lymphocyte ratio, 
but not the C-reactive protein levels, were significantly higher than those in controls. sCD40L was independently 
associated with the presence of obstructive coronary artery disease in multivariate analysis. Regarding CCS severity, 
sCD40L levels showed a significant stepwise increase with increasing angina severity (ANOVA P=0.001). In addi-
tion, sCD40L was independently associated with the anatomical severity of coronary artery disease, as assessed by 
the Gensini score. Among patients with CCS, those with previous coronary artery bypass grafting (n=23) had lower 
sCD40L levels than patients waiting for revascularization (n=45) [4.3 (2.1) ng/mL vs. 6.8 (3.5) ng/mL, P=0.001]. 
Conclusions: The expression of the proinflammatory sCD40L was associated with the presence of CCS and reflected 
the clinical and anatomical severity of CCS. In addition, we describe for the first time the association between prior 
CABG and reduced sCD40L levels in patients with CCS.
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Introduction
Atherosclerosis is recognized as an inflamma-
tory disease, although the underlying inflam- 
matory pathways associated with atheroscle-
rotic disease initiation and progression are not 
completely understood [1-3]. Identifying major 
inflammatory mediators that participate in ath-
erosclerosis regulation may contribute to not 
only a better understanding of pathophysiology 
but also clinical care, since they may potentially 
be used as diagnostic biomarkers and thera-
peutic targets, such as in the Canakinumab 
Antiinflammatory Thrombosis Outcome Study 
[1-4]. 
The soluble form of CD40 ligand (sCD40L) is a 
mediator of vascular inflammation that inter-
acts with the CD40 receptor expressed on dif-
ferent cells involved in atherogenesis, including 
macrophages, endothelial cells and T-cells [5, 
6]. Furthermore, we have previously observed 
that sCD40L expression is associated with vas-
cular function [7, 8]. Altogether, the role of 
sCD40L in chronic coronary syndrome
330 Am J Cardiovasc Dis 2020;10(4):329-339
sCD40L in vascular inflammation and function 
supports sCD40L as a mediator of atheroscle-
rosis expression [5-8]. sCD40L has been ex- 
tensively studied mechanistically and as a 
potential diagnostic and prognostic marker in 
patients with acute coronary syndrome [6-10]. 
Less is known about the role of sCD40L in 
chronic coronary syndromes (CCSs). CCS, a 
recently introduced concept that encompass- 
es stable coronary artery disease, has a pa- 
thophysiology that is distinct from that of acute 
coronary syndrome since inflammation mainly 
regulates the initiation and progression of sta-
ble lesions in CCS; therefore, the study of in- 
flammation specifically in CCS deserves speci- 
al attention [1, 2, 11]. Some studies reported 
higher levels of sCD40L in patients with CCS 
than in controls [12-14], while other studies did 
not [15-20]. However, most of these studies 
have limitations regarding the sample size, 
method used for the exclusion of coronary 
artery disease, and lack of proper adjustment 
for confounding variables [12-20]. More impor-
tantly, there are few data on the relationship 
between sCD40L levels and the clinical or ana-
tomical severity of CCS [20]. 
We aimed to evaluate whether the serum levels 
of sCD40L are associated with 1) the presen- 
ce of CCS, and 2) the clinical and anatomical 
severity of CCS. We hypothesize that sCD40L 
levels are increased in CCS with obstructive 
coronary artery disease and that higher sCD40L 
levels are associated with increased severity 
of CCS.
Materials and methods
The study protocol was approved by the ethics 
committees of the involved institutions (Cen- 
tro Hospitalar Universitário de Lisboa Central, 
Nr. 245/2015, and NOVA Medical School/Fa- 
culdade de Ciências Médicas, Universidade 
NOVA de Lisboa, Nr. 000176). The investigati- 
on conformed to the principles outlined in the 
Declaration of Helsinki. All participants signed 
informed consent forms.
Selection of participants
We prospectively recruited 94 participants fol-
lowed in our center, which were assigned to two 
groups: 26 individuals without coronary artery 
disease (controls) and 68 patients with CCS. 
Inclusion criteria: 1) Controls were recruited 
from the outpatient clinic and were eligible if 
they presented no effort angina; no evidence of 
coronary artery disease on coronary comput- 
ed tomography angiography, including calcium 
score =0 and no soft plaques; and no positive 
myocardial stress test (the latter was not man-
dated to be assessed per protocol); and 2) 
Patients with CCS were recruited from those 
referred for elective invasive coronary angiog-
raphy and were eligible in case of documented 
obstructive coronary artery disease, including 
luminal stenosis of at least 50% for the left 
main artery or at least 70% for other epicardial 
vessels. 
Exclusion criteria: Patients with acute athero-
sclerotic events or coronary artery bypass graf- 
ting (CABG) within 12 months; those with any 
previous percutaneous coronary intervention, 
heart failure, hemodynamically significant val-
vular heart disease, hematological disorders, 
active infection, history of malignancy, chronic 
kidney disease (stage 4 or 5), or severe hepatic 
dysfunction; those under 18 years of age; or 
those unable or unwilling to consent to study 
participation were excluded. If performed at 
least 12 months before inclusion, CABG was 
not an exclusion criterion since the presence 
and extent of coronary artery lesions, which 
were the focus of this study, are not affected 
by the surgical placement of coronary artery 
bypass grafts [21].
Data collection
Clinical, laboratory and anatomical data were 
collected prospectively after patient inclusion. 
A standardized record of clinical and demo-
graphic characteristics (including cardiovascu-
lar risk factors, ongoing medication, clinical 
symptoms, and physical data), hematological 
and biochemical parameters, echocardiogra- 
phic data, and angiography results was obtain- 
ed from each participant. For the assessment 
of the anatomical severity of coronary artery 
disease, we assessed, for each patient, the 
number of obstructive lesions (luminal stenos- 
is of at least 50% for the left main artery or at 
least 70% for other epicardial vessels); the 
number of vessels with obstructive lesions (the 
left main artery, left anterior descending arte- 
ry, circumflex artery and right coronary artery 
were considered separately, with total score 
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ranging from 0 to 4); and the Gensini score, 
which was calculated as previously described 
[22].
Blood sampling and sCD40L measurements
Peripheral blood was collected early in the 
morning under fasting conditions. Serum was 
separated by centrifugation (500 g for 10 min) 
within 15 min of sampling. Aliquots were stor- 
ed at -80°C; samples were thawed only once. 
Concentrations of sCD40L were measured in 
serum by an enzyme-linked immunosorbent 
assay commercial kit (R&D Systems). Each 
sample was measured in duplicate. The intra-
assay variation among the duplicates for all 
samples was less than 10%.
Sample size
A sample size of 20 controls and 60 patients 
with CCS simultaneously provided: 1) 80% 
power to detect a 20% difference in sCD40L 
levels between controls and patients (for the 
first objective), with a standard deviation (SD) 
of sCD40L levels of 35% [12-14], at a 5% sig- 
nificance level; 2) a number of patients with 
CCS enough to carry out a comprehensive anal-
ysis on the association between sCD40L levels 
and CCS severity (for the second objective), 
including a potential multivariate linear regres-
sion analysis [23, 24]. The recruitment was car-
ried out in a control:patient ratio of 1:3, match-
ing by age and sex. Accounting for potential 
dropouts, additional participants were recruit-
ed. There were no dropouts and a total of 26 
controls and 68 patients were included.
Statistical analysis
Discrete data are presented as frequencies 
(percentages), and continuous variables are 
presented as the mean (SD) or the median 
(interquartile range, IQR). Continuous variabl- 
es were analyzed using Student’s t-test or the 
Mann-Whitney test when normality was not 
verified (Shapiro-Wilk test); analysis of variance 
(ANOVA) was used for comparisons between 
multiple patient groups, and Bonferroni post 
hoc correction was used for multiple compari-
sons. Categorical variables were analyzed us- 
ing the chi-squared or Fisher’s exact tests. 
Pearson’s correlation was used to test corre- 
lations between continuous variables. Multi- 
variate logistic regression analysis was appli- 
ed to identify which parameters were indepen-
dently associated with the presence of obstr- 
uctive coronary artery disease and (post hoc 
analysis) with previous CABG. Multivariate lin-
ear regression analysis was used to identify 
the independent predictors of the anatomical 
severity of coronary artery disease, as assess- 
ed by the Gensini score. Outliers were exclud-
ed, as appropriate [25]. The level of significan- 
ce considered was α=0.05. Analyses were con-
ducted with SPSS software, version 26 (IBM).
Results
Clinical and laboratory characteristics of par-
ticipants
The characteristics of the 26 controls and 68 
patients with CCS are presented in Table 1. In 
patients with CCS, hypertension, dyslipidemia, 
diabetes, a smoking history (current or past), 
and the use of antiplatelet and statin therapy 
were significantly more prevalent. In the CCS 
group, leukocyte count, neutrophil count, neu-
trophil/lymphocyte ratio, the percentage of gly-
cosylated hemoglobin, creatinine levels, and 
sCD40L levels were significantly higher, and 
high-density lipoprotein (HDL) cholesterol lev-
els were significantly lower, than in the control 
group. Of note, C-reactive protein levels did not 
differ between groups. 
Association of sCD40L with clinical and labora-
tory data
sCD40L showed a weak positive correlation 
with leukocyte count, neutrophil count, lympho-
cyte count, and platelet count and a weak ne- 
gative correlation with HDL-cholesterol levels 
(Table 2). The sCD40L levels did not differ 
according to age, sex or other cardiovascular 
risk factors and showed no correlation with 
other laboratory parameters, including C-rea- 
ctive protein levels (Table 2).
sCD40L and the presence of obstructive coro-
nary artery disease
Considering all clinical and laboratory data, 
sCD40L was an independent predictor of ob- 
structive coronary artery disease in the multi-
variate logistic regression analysis, in additi- 
on to hypertension and HDL-cholesterol levels 
(Table 3). 
sCD40L in chronic coronary syndrome
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sCD40L and the severity of obstructive coro-
nary artery disease
Clinically, the sCD40L levels showed a step- 
wise increase with increasing severity of angi- 
na among patients with obstructive coronary 
artery disease (ANOVA P=0.001) (Figure 1). An- 
atomically, there was a weak positive correla-
tion between sCD40L levels and the number of 
coronary artery vessels with obstructive dis-
ease (r=0.285, P=0.006), the number of ob- 
structive coronary artery lesions (r=0.238, P= 
0.022), and the Gensini score (r=0.279, P= 
0.007). The levels of sCD40L were higher in 
higher categories of the Gensini score (ANOVA 
P=0.026) (Figure 2). 
The univariate analysis assessing parameters 
associated with the Gensini score (as a contin-
uous variable) is presented in Table 4. In the 
multivariate linear regression analysis, sCD40L 
was an independent predictor of coronary ar- 
tery disease severity, as assessed by the 
Gensini score, in addition to neutrophil/lym- 




Patients with CCS 
(n=68) p-value
Clinical data
    Age, years 61.3 (9.4) 64.8 (9.3) 0.099
    Male, n (%) 23 (88.5) 61 (89.7) 1.000
    Hypertension, n (%) 14 (53.8) 64 (94.1) <0.001
    Dyslipidemia, n (%) 18 (69.2) 65 (95.6) <0.001
    Diabetes mellitus, n (%) 3 (11.5) 29 (42.6) 0.007
    Smoking history (current or past), n (%) 6 (23.1) 37 (54.4) 0.006
    Previous coronary artery bypass grafting, n (%) 0 (0.0) 23 (33.8) <0.001
    Left ventricular ejection fraction > 50%, n (%) 26 (100.0) 68 (100.0) -
    Antiplatelet agent, n (%) 6 (23.1) 66 (97.1) <0.001
    Statin therapy, n (%) 13 (50.0) 61 (89.7) <0.001
Laboratory data
    Hemoglobin, g/dL 13.9 (1.3) 13.6 (1.6) 0.380
    Leukocyte count, 10^9/L 6.4 (1.7) 7.6 (1.8) 0.012
    Neutrophil count, 10^9/L 3.5 (1.5) 4.4 (1.5) 0.010
    Lymphocyte count, 10^9/L 2.0 (0.5) 2.1 (0.8) 0.722
    Neutrophil/lymphocyte ratio 1.9 (0.7) 2.4 (1.1) 0.029
    Platelet count, 10^9/L 230.1 (58.8) 222.6 (51.1) 0.546
    Fasting glycaemia, mg/dL 95.3 (35.1) 112.7 (52.5) 0.124
    Percentage of glycosylated hemoglobin 5.8 (1.2) 6.4 (1.5) 0.014
    Creatinine, mg/dL 0.8 (0.2) 1.0 (0.3) 0.001
    Total cholesterol, mg/dL 186.0 (50.7) 166.4 (45.9) 0.082
    LDL-cholesterol, mg/dL 111.3 (44.2) 100.9 (37.7) 0.261
    HDL-cholesterol, mg/dL 51.5 (13.1) 37.6 (9.1) <0.001
    Triglycerides, mg/dL 133.6 (50.9) 149.0 (55.8) 0.234
    C-reactive protein, mg/L 4.1 (2.0) 3.7 (1.7) 0.334
    sCD40L, ng/mL 4.0 (1.5) 5.9 (3.3) 0.018
Anatomical data
    Nr. of vessels with obstructive disease 0 (0.0) 2.9 (0.8) <0.001
    Nr. of obstructive lesions 0 (0.0) 4.0 (1.4) <0.001
    Gensini score 0 (0.0) 72.9 (42.5) <0.001
Data are expressed as mean (SD), except if otherwise specified. CCS - chronic coronary syndrome; HDL - high-density lipopro-
tein; LDL - low-density lipoprotein; Nr. - number; sCD40L - soluble CD40 ligand.
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phocyte ratio, creatinine levels, and HDL-ch- 
olesterol levels (Table 5). 
sCD40L and previous coronary revasculariza-
tion
Among the 68 patients with CCS, 23 had pre- 
viously undergone CABG (median 36 months, 
IQR 14 months to 10 years, before recruit-
ment), and 45 had not been previously revas- 
cularized. Patients with prior CABG showed 
lower levels of sCD40L [4.3 (2.1) ng/mL vs. 6.8 
(3.5) ng/mL, P=0.001]. Leukocyte, neutrophil, 
and platelet counts were also significantly low- 
er in patients with prior CABG (Table 6). There 
were no other differences between groups, 
including the extent of native coronary artery 
Discussion
In this prospective case-control study, three 
findings stood out: sCD40L levels were higher 
in patients with CCS; sCD40L levels were asso-
ciated with the clinical and anatomical severity 
of coronary artery disease; and prior CABG was 
associated with reduced sCD40L levels among 
patients with CCS.
Regarding the increased levels of sCD40L in 
patients with CCS compared to controls, this 
association was independent from other clini-
cal variables, such as classic cardiovascular 
risk factors, and from laboratory measures, 
such as those reflecting inflammatory activa-
tion, including leukocyte, neutrophil and plate-




Age, yearsb r=-0.085 0.419
Sexc Male 5.5 (3.2) 0.876
Female 5.4 (3.0)
Hypertensionc No 4.9 (2.4) 0.555
Yes 5.5 (3.1)
Dyslipidemiac No 5.3 (2.4) 0.953
Yes 5.4 (3.1)
Diabetes mellitusc No 5.5 (3.0) 0.555
Yes 5.2 (3.1)
Smoking historyc No 5.1 (2.7) 0.363
Yes 5.9 (3.3)
Laboratory parameters
    Hemoglobin, g/dLb r=0.123 0.243
    Leukocyte count, 10^9/Lb r=0.301 0.004
    Neutrophil count, 10^9/Lb r=0.219 0.037
    Lymphocyte count, 10^9/Lb r=0.292 0.005
    Neutrophil/lymphocyte ratiob r=-0.041 0.704
    Platelet count, 10^9/Lb r=0.223 0.035
    Fasting glycaemia, mg/dLb r=0.114 0.284
    Percentage of glycosylated hemoglobinb r=0.136 0.217
    Creatinine, mg/dLb r=0.118 0.258
    Total cholesterol, mg/dLb r=-0.017 0.874
    LDL-cholesterol, mg/dLb r=0.014 0.897
    HDL-cholesterol, mg/dLb r=-0.222 0.036
    Triglycerides, mg/dLb r=0.039 0.717
    C-reactive protein, mg/Lb r=0.095 0.388
aSoluble CD40 ligand levels are expressed as mean (SD); bCorrelations between soluble 
CD40 ligand levels and continuous variables were tested and the correlation coefficient 
(r) is presented for each; csoluble CD40 ligand levels were compared between groups 
for categorical variables. HDL - high-density lipoprotein; LDL - low-density lipoprotein; 
sCD40L - soluble CD40 ligand.
disease (Table 6). In the 
multivariate logistic regre- 
ssion analysis, sCD40L 
was the only parameter 
independently associated 
with previous surgical re- 
vascularization (β 0.736, 
95% confidence interval 
0.597 to 0.908, P=004). 
There was no correlation 
between time elapsed fr- 
om CABG and sCD40L lev-
els (r=-0.263, P=0.225). 
When patients with prior 
CABG were classified ac- 
cording to the median ti- 
me elapsed from CABG 
(36 months), there were 
no differences regarding 
the severity of coronary 
artery disease (Table 7) or 
sCD40L levels [5.0 (2.3) 
ng/mL vs. 3.6 (1.6) ng/
mL, if time elapsed from 
CABG was inferior to or at 
least 36 months, respec-
tively, p=0.098]. 
Of note, a post hoc multi-
variate analysis on pre- 
dictors of obstructive cor-
onary artery disease, ex- 
cluding patients with CCS 
and prior CABG (Table 8), 
yielded similar results to 
the multivariate analysis 
including all patients with 
CCS (Table 3).
sCD40L in chronic coronary syndrome
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Table 3. Predictors of obstructive stable coronary artery disease by 
multivariate logistic regression analysis
Predictors β 95% CI p-value
Hypertension 0.055 0.010 to 0.305 0.001
HDL-cholesterol, mg/dL 0.885 0.825 to 0.949 0.001
sCD40L, ng/mL 1.329 1.005 to 1.757 0.046
95% CI - 95% confidence interval; HDL - high-density lipoprotein; sCD40L - soluble 
CD40 ligand.
Figure 1. Soluble CD40 ligand levels according to angina class, among pa-
tients with obstructive coronary artery disease. Soluble CD40 ligand values 
are expressed as ng/mL, mean (SD). CCS - Canadian Cardiovascular Society 
(angina class); sCD40L - soluble CD40 ligand. * p-value <0.05 vs. angina 
class I; ¥ p-value <0.05 vs. angina class II.
Figure 2. Soluble CD40 ligand levels according to the Gensini score. The first 
group corresponds to controls (all of which had a Gensini score of zero), and 
the remaining participants were equally divided into three groups according 
to the Gensini score. Soluble CD40 ligand values are expressed as ng/mL, 
mean (SD). sCD40L - soluble CD40 ligand. * p-value <0.05 vs. Gensini score 
of zero.
let counts and C-reactive protein levels. Some 
previous studies also reported higher levels of 
sCD40L in the presence of stable coronary 
artery disease [12-14], while 
others did not [15-20]. How- 
ever, some of these studies 
have limitations regarding sa- 
mple size [14, 16-19]. On the 
other hand, in previous stud-
ies, the exclusion of coronary 
artery disease in controls was 
based on invasive coronary 
angiography or on clinical as- 
sessment without an evalua-
tion of coronary anatomy [12-
20]. We used coronary com-
puted tomography angiogra-
phy to exclude coronary arte- 
ry atherosclerosis in controls, 
which may have a higher ne- 
gative predictive power than 
invasive coronary angiography 
[26]; indeed, invasive coro-
nary angiography visualizes 
only luminal narrowing and 
may be insensitive to corona- 
ry artery lesions with positive 
remodeling and no compro-
mise of luminal dimensions, 
which are conversely detect-
able by coronary computed 
tomography angiography [26]. 
In addition, most studies that 
tested sCD40L as a potential 
predictor of the presence of 
obstructive coronary artery di- 
sease lack proper adjustment 
for confounding variables [12, 
14, 16-20]. We conducted 
a comprehensive multivariate 
analysis, which confirmed the 
independent association bet- 
ween sCD40L and coronary 
artery disease status. 
Second, we observed that 
sCD40L was consistently and 
independently associated wi- 
th the severity of coronary 
artery disease. There are few 
data available on this subject, 
and our results provide furth- 
er insights into the pathop- 
hysiology of CCS presentation 
and severity. Previous studi- 
es reported no association 
between sCD40L levels and the anatomical 
severity of coronary artery disease, assessed 
by an angiographic score [12, 27] or by coro-
sCD40L in chronic coronary syndrome
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Age, yearsb r=0.201 0.053
Sexc Male 53.6 (49.9) 0.877
Female 45.3 (39.4)
Hypertensionc No 25.9 (53.4) 0.002
Yes 58.2 (46.2)
Dyslipidemiac No 12.4 (32.2) 0.001
Yes 58.1 (48.2)
Diabetes mellitusc No 49.1 (51.4) 0.170
Yes 59.7 (43.1)
Smoking historyc No 54.5 (53.3) 0.105
Yes 48.4 (36.2)
Laboratory parameters
    Hemoglobin, g/dLb r=0.066 0.530
    Leukocyte count, 10^9/Lb r=0.294 0.005
    Neutrophil count, 10^9/Lb r=0.265 0.011
    Lymphocyte count, 10^9/Lb r=0.000 0.999
    Neutrophil/lymphocyte ratiob r=0.309 0.003
    Platelet count, 10^9/Lb r=-0.048 0.650
    Fasting glycaemia, mg/dLb r=0.031 0.771
    Percentage of glycosylated hemoglobinb r=0.044 0.689
    Creatinine, mg/dLb r=0.322 0.002
    Total cholesterol, mg/dLb r=-0.149 0.156
    LDL-cholesterol, mg/dLb r=-0.064 0.543
    HDL-cholesterol, mg/dLb r=-0.450 <0.001
    Triglycerides, mg/dLb r=0.064 0.545
    C-reactive protein, mg/Lb r=0.066 0.549
    sCD40L, ng/mLb r=0.279 0.007
aThe Gensini score is expressed as mean (SD); bCorrelations between the Gensini 
score and continuous variables were tested and the correlation coefficient (r) is 
presented for each; cThe Gensini score was compared between groups for categori-
cal variables. HDL - high-density lipoprotein; LDL - low-density lipoprotein; sCD40L 
- soluble CD40 ligand.
Table 5. Predictors of the Gensini score by multivariate linear 
regression analysis
Predictors β 95% CI p-value
Neutrophil/lymphocyte ratio 12.821 4.017 to 21.625 0.005
Creatinine, mg/dL 33.284 4.393 to 62.176 0.024
HDL-cholesterol, mg/dL -1.205 -1.989 to -0.421 0.003
sCD40L, ng/mL 3.177 0.276 to 6.078 0.032
95% CI - 95% confidence interval; HDL - high-density lipoprotein; sCD40L - soluble 
CD40 ligand.
nary artery calcium score [28]. Nevertheless, 
theses scores do not assign a specific weight 
for each diseased segment and therefore do 
not account for the perfused 
territories supplied by steno-
ses located in different seg-
ments [12, 27, 28]. We used 
the Gensini score, which si- 
multaneously measures cor-
onary artery disease burden 
and considers the myocardi-
um at risk for each lesion/
segment [22]. This may ex- 
plain our positive findings in 
contrast to those of the afo- 
rementioned studies. In fact, 
of the studies focusing on 
stable coronary artery dis-
ease, one reported increas- 
ed sCD40L levels in multi-
vessel disease compared to 
less severe disease and a 
positive correlation between 
sCD40L and the Gensini sc- 
ore [29]. Additional data on 
the relationship between sta-
ble coronary artery disease 
severity and sCD40L levels 
are scarce. On the other 
hand, to the best of our 
knowledge, there are no pub-
lished data on the associa-
tion between angina severity, 
as a measure of the clinical 
severity of CCS, and sCD40L. 
Therefore, our results may 
add to the knowledge on 
how inflammation may indi-
rectly be reflected in clinical 
status.
Third, we describe for the fir- 
st time the variation in sCD- 
40L levels according to co- 
ronary revascularization sta-
tus. In addition to having a 
causal role in atheroscleros- 
is development, sCD40L mi- 
ght itself be influenced by 
atherosclerosis and reflect 
coronary artery disease bur-
den and ischemic stress 
[30]. Indeed, in our sample, 
among patients with CCS, 
those with previous CABG showed lower le- 
vels of sCD40L than patients without previous 
CABG. It is known that severe chronic coronary 
sCD40L in chronic coronary syndrome
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    Age, years 64.9 (10.2) 64.7 (7.3) 0.645
    Male, n (%) 41 (91.1) 20 (87.0) 0.681
    Hypertension, n (%) 43 (95.6) 21 (91.3) 0.599
    Dyslipidemia, n (%) 42 (93.3) 23 (100.0) 0.546
    Diabetes mellitus, n (%) 20 (44.4) 9 (39.1) 0.675
    Smoking history (current or past), n (%) 26 (57.8) 11 (47.8) 0.436
    Left ventricular ejection fraction > 50%, n (%) 45 (100.0) 23 (100.0) -
    Antiplatelet agent, n (%) 43 (95.6) 23 (100.0) 0.546
    Statin therapy, n (%) 40 (88.9) 21 (91.3) 1.000
Laboratory data
    Hemoglobin, g/dL 13.6 (1.5) 13.7 (1.8) 0.780
    Leukocyte count, 10^9/L 8.0 (1.8) 6.7 (1.6) 0.003
    Neutrophil count, 10^9/L 4.8 (1.4) 3.8 (1.7) 0.001
    Lymphocyte count, 10^9/L 2.2 (0.9) 1.8 (0.7) 0.133
    Neutrophil/lymphocyte ratio 2.4 (1.0) 2.3 (1.1) 0.457
    Platelet count, 10^9/L 233.6 (49.3) 199.7 (47.9) 0.011
    Fasting glycaemia, mg/dL 113.7 (50.1) 110.5 (58.1) 0.892
    Percentage of glycosylated hemoglobin 6.6 (1.5) 6.1 (1.3) 0.171
    Creatinine, mg/dL 1.1 (0.4) 1.0 (0.3) 0.367
    Total cholesterol, mg/dL 170.9 (42.6) 157.9 (51.6) 0.274
    LDL-cholesterol, mg/dL 104.4 (35.5) 94.1 (41.6) 0.291
    HDL-cholesterol, mg/dL 37.6 (8.9) 37.6 (9.6) 0.859
    Triglycerides, mg/dL 155.6 (57.9) 136.0 (52.3) 0.169
    C-reactive protein, mg/L 3.6 (1.3) 3.8 (1.9) 0.611
    sCD40L, ng/mL 6.8 (3.5) 4.3 (2.1) 0.001
Anatomical data
    Nr. of vessels with obstructive disease 3.0 (0.9) 2.8 (0.7) 0.438
    Nr. of obstructive lesions 4.1 (1.2) 3.8 (1.6) 0.243
    Gensini score 71.1 (36.2) 76.3 (53.5) 0.928
Data are expressed as mean (SD), except if otherwise specified. CABG - coronary artery bypass grafting; HDL - high-density 
lipoprotein; LDL - low-density lipoprotein; Nr. - number; sCD40L - soluble CD40 ligand.
Table 7. Severity of native coronary artery disease according to time elapsed from coronary artery 
bypass grafting
CABG 12 to 36 months 
before (n=12)
CABG at least 36 months 
before (n=11) p-value
Nr. of vessels with obstructive disease 2.8 (0.7) 2.8 (0.8) 0.961
Nr. of obstructive lesions 3.8 (1.5) 3.8 (1.7) 0.920
Gensini score 68.8 (49.1) 84.5 (59.2) 0.493
Data are expressed as mean (SD). CABG - coronary artery bypass grafting; Nr. - number.
ischemia promotes the release of reactive oxy-
gen species, cytokines and other inflammatory 
markers and that revascularization may amelio-
rate inflammation and vascular function [31, 
32]. It is possible that the reduction of ischemic 
stress after bypass grafting may have reduc- 
ed inflammation without modifying coronary 
atherosclerosis burden, which translated into 
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Table 8. Independent predictors of obstructive 
coronary artery disease excluding patients with prior 
coronary artery bypass grafting
Predictors β 95% CI p-value
Hypertension 0.058 0.007 to 0.464 0.007
HDL-cholesterol, mg/dL 0.893 0.828 to 0.964 0.004
sCD40L, ng/mL 1.344 1.016 to 1.778 0.038
95% CI - 95% confidence interval; HDL - high-density lipoprotein; 
sCD40L - soluble CD40 ligand.
lower sCD40L release into peripheral blood 
[21]. The hypothesis that sCD40L is a surrogate 
of coronary artery disease burden and myocar-
dial ischemic stress needs to be explored in 
future studies. The scarce data available on the 
long-term effects of CABG on inflammation in 
patients with CCS point to an attenuation of the 
acute-phase reaction, reflected by a reduction 
in C-reactive protein levels [33]. Specifically, for 
sCD40L, the levels were reported to rise imme-
diately after CABG, probably due to endothelial 
disruption and inflammatory activation related 
to the surgery itself, followed by a decrease in 
the first month after surgery [34]. Nevertheless, 
no published long-term data are available. 
There are strengths of this study that should 
be acknowledged. The prospective nature of 
the study, the use of coronary computed tomo- 
graphy angiography to exclude coronary artery 
atherosclerosis in controls and, importantly, 
the multivariate analysis adjusting for confo- 
unders contributed to higher accuracy in the 
identification of sCD40L as a predictor of ob- 
structive coronary artery disease compared to 
previous studies. In addition, analyses on the 
clinical and anatomical severity of CCS, with 
adjustment for confounding variables, added 
consistency to the results. To the best of our 
knowledge, the association between the clini-
cal severity of CCS and sCD40L levels has not 
yet been reported. Finally, we describe for the 
first time a reduced expression of sCD40L in 
patients with prior coronary revascularization 
among those with obstructive coronary artery 
disease.
Our study has some limitations. First, this is a 
single-center study and additional studies from 
multiple centers are warranted. Second, we did 
not demonstrate a causal relationship between 
sCD40L and atherogenesis, which has already 
been studied [6, 35]. Instead, we observed th- 
at sCD40L probably mediates the interaction 
between inflammation and atherosclero- 
tic disease expression, and may also be 
a surrogate marker. The consistency of our 
results, considering the multiple results 
pointing towards the same direction, af- 
ter adjustment for confounders, reinforces 
the role of sCD40L as a mediator in this 
process.
In conclusion, the sCD40L levels were in- 
creased in patients with CCS, and sCD- 
40L expression was associated with the clini- 
cal and anatomical severity of CCS, while coro-
nary artery revascularization was associated 
with the attenuation of sCD40L dysregulation. 
Therefore, sCD40L may participate in the as- 
sociation between inflammation and athero-
sclerosis development, progression and clini- 
cal expression. The results of this study add to 
knowledge on the pathophysiology of coronary 
atherosclerosis. In addition, our findings sug-
gest that sCD40L may be a promising comple-
mentary noninvasive tool for refining the stra- 
tification of coronary atherosclerosis burden 
and severity, which could contribute to the tai-
loring of the primary prevention strategies. 
These fields deserve further research.
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